OCA
OKUR

Octagon Capital Advisors’s OnKure Therapeutics OKUR Stock Holding History

Octagon Capital Advisors’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-225,000
Closed -$3.83M – 49
2024
Q3 		$3.83M Hold
225,000
– – 0.6% 29
2024
Q2 		$3.4M Hold
225,000
– – 0.53% 33
2024
Q1 		$3.73M Hold
225,000
– – 0.45% 42
2023
Q4 		$3.6M Sell
225,000
-2,987
-1% -$186K 0.58% 24
2023
Q3 		$17.4M Sell
227,987
-8,872
-4% -$603K 2.67% 13
2023
Q2 		$15.5M Buy
236,859
+194,859
+464% +$15.7M 2.16% 13
2023
Q1 		$2.51M Buy
+42,000
New +$1.52M 0.36% 29

Other funds holding OKUR

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Octagon Capital Advisors's OKUR Position: Q4 2024 in Review

Octagon Capital Advisors sold out of OnKure Therapeutics (OKUR) in Q4 2024, closing a stake of 225,000 shares — an estimated $3.83M sold.

Octagon Capital Advisors first reported a position in OKUR in Q1 2023 and held it in 7 quarters. The position peaked at $17.4M in Q3 2023. 51 funds tracked by Wall St. Rank hold OKUR as of Q4 2024.

  • Octagon Capital Advisors reported no remaining OnKure Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Octagon Capital Advisors sold 225,000 OnKure Therapeutics shares in Q4 2024, an estimated $3.83M.
  • Octagon Capital Advisors first reported a position in OnKure Therapeutics in Q1 2023 and held it in 7 quarters.
  • Octagon Capital Advisors's OnKure Therapeutics position peaked at $17.4M in Q3 2023.
  • 51 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q4 2024.

Based on Octagon Capital Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.